Vaxart, Inc.
For the period ended Aug 13, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 13, 2025 · Filed Aug 13, 2025
Use the contents to explore the available documents and sections.
VXRT$0.550.0%Stored close · as of Jul 8, 2026
Contents
EX-99.1 · Influenza Program Developments
Influenza Program Developments
| ● | Vaxart continues to advance its avian influenza program. The new avian influenza vaccine was 100% protective against death in a robust ferret clade 2.3.4.4b challenge model, compared with 0% survival in placebo-treated animals. Vaxart intends to publish the results of the preclinical studies in a peer-reviewed forum when the full study analysis is complete. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.